Global cancer drug prices have increased by 10 percent every year between 1995 and 2013. That level of price inflation is not sustainable or winning pharma any friends. In this expert report, U.S. and E.U. payers note that monopolistic pricing for novel products that represent the only therapeutic option, or the high prices demanded for treatments with minimal therapeutic benefits, cannot always be afforded or justified.
Moderate payers are looking to pharma to act, less moderate payers want government intervention and price controls. Pharma risks killing the goose that laid the golden egg and payers warn it’s time to get real about cancer drug pricing if pharma wants widespread reimbursement and market access.